Two-year and lifetime cost-effectiveness of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for head-and-neck cancer

International Journal of Radiation Oncology Biology Physics

Volumn 87, Issue 4, 2013, Pages 683-689

  Kohler, Racquel E ^a   Sheets, Nathan C ^b   Wheeler, Stephanie B ^a   Nutting, Chris ^c   Hall, Emma ^d   Chera, Bhishamjit S ^b  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADDITIONAL DATUM; AVERAGE LIFE EXPECTANCY; CONFORMAL RADIATION THERAPY; COST-EFFECTIVENESS RATIOS; HEAD-AND-NECK CANCER; INITIAL TREATMENT; INTENSITY-MODULATED RADIATION THERAPY; METHODS AND MATERIALS;

COST EFFECTIVENESS; DISEASES; HEALTH INSURANCE; MARKOV PROCESSES; RADIOTHERAPY; THREE DIMENSIONAL;

PHYSICAL THERAPY;

AGED; ARTICLE; CANCER RADIOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DYSPHAGIA; FOLLOW UP; HEAD AND NECK CANCER; HEALTH STATUS; HOSPITALIZATION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LIFE EXPECTANCY; LIFESPAN; MAJOR CLINICAL STUDY; MEDICARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RADIOTHERAPY; REIMBURSEMENT; TERMINAL CARE; THREE DIMENSIONAL CONFORMAL RADIATION THERAPY; TREATMENT DURATION; XEROSTOMIA;

AGED; COST-BENEFIT ANALYSIS; DEGLUTITION DISORDERS; HEAD AND NECK NEOPLASMS; HUMANS; LIFE EXPECTANCY; MARKOV CHAINS; MEDICARE; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TIME FACTORS; UNITED STATES; XEROSTOMIA;

EID: 84885990238     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.08.011     Document Type: Article

References (25)

1. B.B.A. Guadagnolo Evaluation of trends in the use of intensity-modulated radiotherapy for head and neck cancer from 2000 through 2005: Socioeconomic disparity and geographic variation in a large population-based cohort BMC Cancer 116 2010 3505 3512
2. C.C.M. Nutting Improvements in target coverage and reduced spinal cord irradiation using intensity-modulated radiotherapy (IMRT) in patients with carcinoma of the thyroid gland Radiother Oncol 60 2001 173 180
3. C.M. Nutting, J.P. Morden, and K.J. Harrington Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): A phase 3 multicentre randomised controlled trial Lancet Oncol 12 2011 127 136
4. E.E.H. Pow Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: Initial report on a randomized controlled clinical trial Int J Radiat Oncol Biol Phys 66 2006 981 991
5. M.M.K.M. Kam Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients J Clin Oncol 25 2007 4873 4879
6. M. Scott-Brown, A. Miah, and K. Harrington Evidence-based review: Quality of life following head and neck intensity-modulated radiotherapy Radiother Oncol 97 2010 249 257
7. E.B. Elkin, and P.B. Bach Cancer's next frontier JAMA 303 2010 1086 1087
8. S. Ramsey, C. Fedorenko, and K. Snell Cancer diagnosis as a risk factor for personal bankruptcy J Clin Oncol 29 2011 6007
9. B.R. Paliwal, and I.A. Brezovich IMRT may be used to excess because of its higher reimbursement from medicare Med Phys 31 2004 1
10. B.B.L.T. Ramaekers The impact of late treatment-toxicity on generic health-related quality of life in head and neck cancer patients after radiotherapy Oral Oncol 47 2011 768 774
11. D.I. Rosenthal, J.S. Lewin, and A. Eisbruch Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer J Clin Oncol 24 2006 2636 2643
12. K.U. Hunter, M. Schipper, and F.Y. Feng Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: Prospective study of patient-reported, observer-rated, and objective outcomes Int J Radiat Oncol Biol Phys 85 2013 935 940
13. P. Rubin, L.S. Constine, and L.F. Fajardo Overview: Late effects of normal tissues (LENT) scoring system Int J Radiat Oncol Biol Phys 31 1995 1041 1042
14. J. Pavy, J. Denekamp, and J. Letschert EORTC late effects working group. Late effects toxicity scoring: The SOMA scale Int J Radiat Oncol Biol Phys 31 1995 1043 1047
15. K.F. Ho, D.J.J. Farnell, and J.A. Routledge Comparison of patient-reported late treatment toxicity (LENT-SOMA) with quality of life (EORTC QLQ-C30 and QLQ-H&N35) assessment after head and neck radiotherapy Radiother Oncol 97 2010 270 275
16. G.O. Schoenfeld, R.J. Amdur, and C.G. Morris Patterns of failure and toxicity after intensity-modulated radiotherapy for head and neck cancer Int J Radiat Oncol Biol Phys 71 2008 377 385
17. A. Eisbruch, J. Harris, and A.S. Garden Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22) Int J Radiat Oncol Biol Phys 76 2010 1333 1338
18. M.R. Gold, J.E. Siegel, and L.B. Russell Cost-Effectiveness in Health and Medicine 1996 Oxford University Press New York
19. K.K. Ang, J. Harris, and R. Wheeler Human papillomavirus and survival of patients with oropharyngeal cancer N Engl J Med 363 2010 24 35
20. C. Fakhry, W.H. Westra, and S. Li Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial J Natl Cancer Inst 100 2008 261 269
21. A.K. Chaturvedi, E.A. Engels, and W.F. Anderson Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the united states J Clin Oncol 26 2008 612 619
22. A.K. Chaturvedi, E.A. Engels, and R.M. Pfeiffer Human papillomavirus and rising oropharyngeal cancer incidence in the united states J Clin Oncol 29 2011 4294 4301
23. J.H. Yong, J. Beca, and B. O'Sullivan Cost-effectiveness of intensity-modulated radiotherapy in oropharyngeal cancer Clin Oncol (R Coll Radiol) 24 2012 532 538
24. S. Jabbari, H.M. Kim, and M. Feng Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: Initial report Int J Radiat Oncol Biol Phys 63 2005 725 731
25. S.B. Jensen, A.M. Pedersen, and A. Vissink A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: Management strategies and economic impact Support Care Cancer 18 2010 1061 1079